Paper9649162
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
Warner E and 10 others. Br J Cancer, 1998. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Papers, record 9649162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9649162
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Neoplasms, Unknown Primary | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Carboplatin | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Etoposide | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4748282 | Letter: Creatinine clearance: bedside estimate. | Ann Intern Med | 1973 | https://conductscience.org/library/papers/4748282 | PubMed |
| 2 | 9196154 | Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9196154 | PubMed |
| 3 | 3933808 | Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. | CMAJ | 1985 | https://conductscience.org/library/papers/3933808 | PubMed |
| 4 | 3548315 | Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. | Am J Clin Oncol | 1987 | https://conductscience.org/library/papers/3548315 | PubMed |
| 5 | 2918334 | Chronic daily administration of oral etoposide--a phase I trial. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2918334 | PubMed |
| 6 | 2669133 | The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site. | Semin Oncol | 1989 | https://conductscience.org/library/papers/2669133 | PubMed |
| 7 | 2681557 | Carboplatin dosage: prospective evaluation of a simple formula based on renal function. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2681557 | PubMed |
| 8 | 2154857 | Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. | Semin Oncol | 1990 | https://conductscience.org/library/papers/2154857 | PubMed |
| 9 | 2154858 | Phase II study of daily oral etoposide in refractory germ cell tumors. | Semin Oncol | 1990 | https://conductscience.org/library/papers/2154858 | PubMed |
| 10 | 1984833 | The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site. | Cancer | 1991 | https://conductscience.org/library/papers/1984833 | PubMed |
| 11 | 1888154 | High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. | Anticancer Res | 1991 | https://conductscience.org/library/papers/1888154 | PubMed |
| 12 | 7684858 | Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. | Semin Oncol | 1993 | https://conductscience.org/library/papers/7684858 | PubMed |
| 13 | 8316270 | Treatment of patients with cancer of an unknown primary site. | N Engl J Med | 1993 | https://conductscience.org/library/papers/8316270 | PubMed |
| 14 | 8156538 | Unknown primary tumours. | Cancer Treat Rev | 1994 | https://conductscience.org/library/papers/8156538 | PubMed |
| 15 | 7636553 | Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. | J Clin Oncol | 1995 | https://conductscience.org/library/papers/7636553 | PubMed |
| 16 | 6321006 | VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. | Cancer | 1984 | https://conductscience.org/library/papers/6321006 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41749818 | Ten-Year Experience in the Treatment of Cancers of Unknown Primary from Poland: From Overall Survival to Factors Influencing Response in the Prepersonalization Era. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749818 | PubMed |
| 41122443 | Epidemiologic, histopathological, and prognostic analysis of cancer of unknown primary in an Iranian population. | J Res Med Sci | 2025 | https://conductscience.org/library/papers/41122443 | PubMed |
| 40242159 | Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40242159 | PubMed |
| 39033323 | Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary. | Mol Ther | 2024 | https://conductscience.org/library/papers/39033323 | PubMed |
| 34075699 | MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. | Mol Oncol | 2021 | https://conductscience.org/library/papers/34075699 | PubMed |
| 33504059 | Cancer of Unknown Primary: Challenges and Progress in Clinical Management. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33504059 | PubMed |
| 32010631 | "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"? | Front Oncol | 2019 | https://conductscience.org/library/papers/32010631 | PubMed |
| 28515916 | ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site. | Mol Clin Oncol | 2017 | https://conductscience.org/library/papers/28515916 | PubMed |
| 19424663 | Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19424663 | PubMed |
| 17180509 | Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. | Int J Clin Oncol | 2006 | https://conductscience.org/library/papers/17180509 | PubMed |
| 15138469 | Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. | Br J Cancer | 2004 | https://conductscience.org/library/papers/15138469 | PubMed |
| 11953879 | A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. | Br J Cancer | 2002 | https://conductscience.org/library/papers/11953879 | PubMed |
| 11429061 | Treatable subsets in cancer of unknown primary origin. | Jpn J Cancer Res | 2001 | https://conductscience.org/library/papers/11429061 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9649162
GET https://conductscience.org/api/papers/v1/9649162/authors